期刊文献+

肠出血性大肠杆菌O157∶H7志贺毒素I型A亚基的表达与鉴定 被引量:2

Expression and identification of enterohemorrhagic Escherichia coli O157 ∶ H7Shiga toxin1A subunit
下载PDF
导出
摘要 目的表达肠出血性大肠杆菌(EHEC)O157∶H7志贺毒素1型A亚基(Stx1A)重组蛋白并鉴定。方法从EHEC O157∶H7基因组中扩增编码Stx1A的基因,经测序无误后,克隆入表达载体pET-22b(+),转化大肠杆菌BL21(DE3),经诱导、纯化获得目的蛋白Stx1A,并对纯化的目的蛋白进行质谱鉴定。重组的Stx1A蛋白免疫BALB/c小鼠,观察小鼠抗血清与EHEC O157∶H7毒株特异性反应。结果 PCR扩增的Stx1A基因为945 bp,成功构建重组质粒pET22b(+)-Stx1a,重组蛋白在原核细胞中获得高效表达,通过AKTATM-His亲和层析柱获得纯化。质谱分析表明目的蛋白为Stx1A。Western blot显示鼠抗Stx1A血清可与EHEC O157∶H7毒株产生的天然毒素蛋白结合。结论成功克隆了EHEC O157∶H7 Stx1A基因,并获得重组表达,为后续研究奠定基础。 Objective To express and identify enterohemorrhagic Escherichia coil (EHEC) O157:H7 Shiga toxin 1 A subunit (SODA). Methods StxlA encoded gene was amplified from EHEC O157:H7 genome by PCR, confirmed by sequencing and cloned into vector pET-22b(+). The recombinant plasmid pET-22b(+)-SODA was transformed into E. coli BL21 (DE3) which was induced by IPTG to express the target protein. After purified by AKTATU-His affinity chromatography, the recombinant protein was identified by mass spectrometry. With the recombinant protein, BALB/c mice were immunized to develop the anti-sera and evaluate its specific reaction with the natural StxtA by Western blotting. Results The SOdA gene with a size of 945 bp was amplified and cloned into prokaryotic expression vector pET22b(+) to form pET-22b(+)-SOdA. The recombinant protein was effectively expressed in E. co//BL21 (DE3) and purified by 6 x His-based affinity chromatography. The mass spectrometry analysis showed that the target protein was StxlA. Western blotting demonstrated that its immunized sera could react specifically with the natural Stx]A. Conclusion The EHEC O157:H7 SOdA gene was successfully cloned and expressed, which laid a solid foundation for the following researches.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2014年第2期121-124,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 江苏省自然科学基金(BK2006242) 江苏省医学重点人才课题(RC2011082)
关键词 肠出血性大肠杆菌O157 H7 志贺毒素1型A亚基 鉴定 EHEC O157:H7 Shiga toxin 1 A subunit identification
  • 相关文献

参考文献15

  • 1Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin- producing Escherichia coli infections[ J]. Clin Microbiol Rev, 1998, 11(3) : 450 -479.
  • 2Loirat C. Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli[J]. La Revue du praticien, 2013, 63( 1 ) : 11 - 16.
  • 3Boerlin P, McEwen SA, Boerlin-Petzold F, et al. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans [ J]. J Clin Microbiol, 1999, 37 ( 3 ) : 497 - 503.
  • 4Sham HP, Shames SR, Crexen MA, et al. Attaching and effacing bacterial effeetor NleC suppresses epithelial inflammatory responses by inhibiting NF-KB and p38 mitogen-aetivated protein kinase activation[J]. Infect Immun, 2011, 79(9) : 3552 -3562.
  • 5焦永军,曾晓燕,郭喜玲,汪华,崔仑标,李显,冯振卿,孙慧,万佳艺,史智扬.肠出血性大肠埃希菌O157:H7Ⅱ型志贺毒素的纯化及功能鉴定[J].中华传染病杂志,2008,26(4):217-220. 被引量:4
  • 6Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants : frequency and association with clinical symptoms[J]. J Infect Dis, 2002, 185(I) : 74 -84.
  • 7Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin- produeing Escherichia coli infeetions[ J]. Clin Microbiol Rev, 1998, 11(3) : 450 -479.
  • 8Pfeiffer ML, DuPont HL, Oehoa TJ. The patient presenting with acute dysentery-a systematie review [ J]. J Infeet, 2012, 64 (4) : 374 - 386.
  • 9Butler T. Haemolytie uraemic syndrome during shigellosis [ J ]. Trans R Soe Trep Med Hyg, 2012, 106(7) : 395 -399.
  • 10Traehtman H, Austin C, Lewinski M, et al. Renal and neurological involvement in typical Shiga toxin-associated HUS [ J ]. Nat Rev Nephrol, 2012, 8 ( I 1 ) : 658 - 669.

二级参考文献39

  • 1邹全明.肠出血性大肠杆菌O157感染防治研究进展[J].微生物学杂志,2004,24(5):96-98. 被引量:21
  • 2Wen SX, Teel LD, Judge NA, et al. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine, 2006, 24: 1142-1148.
  • 3Beatty ME, Bopp CA, Wells JG, et al. Enterotoxinproducing Escherichia coli O169:H41, United States. Emerg Infect Dis, 2004,10: 518-521.
  • 4Tzipori S, Sheoran A, Akiyoshi D, et al. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev, 2004,17: 926-941.
  • 5MacLeod DL, Gyles CL. Purification and characterization of an Escherichia coli Shiga-like toxin Ⅱ variant. Infect Immun, 1990,58:1232-1239.
  • 6Sheoran AS, Chapman S, Singh P, et al. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun, 2003,71: 3125-3130.
  • 7Craig S WONG MD, Srdjan Jelacic BS, Rebecca L Habeeb BS, et al. The risk of the hemolytic - uremic syndrome after antibiotic treatment of Escheichia coli O157:H7 infections[J]. The New England Journal of Medicine, 2000, 29 ,1930-1936.
  • 8Muhldorfer I, Hacker J, Keusch GT, et al. Regulation of the Shiga-like toxin II operon in Escherichia coli [J]. Infect Immun, 1996, 64: 495-502.
  • 9Neidhardt FC. Escherichia coli and Salmonella [M]. ASM Press, Washington, 1996 : 1400-1416.
  • 10Gordon VM ,Whipp SC ,Moon HW ,et al. An enzymatic mutant of Shiga2like toxin Ⅱ variant is a vaccine candidate for edema disease of swine[J]. Infect Immun, 1992, 60:485.

共引文献17

同被引文献60

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部